Eli Lilly’s recently-announced investment into the UK’s life sciences sector “marks a pivotal moment for the industry”, according to GlobalData’s senior analyst in business fundamentals Ophelia Chan.

Considering the £279mn ($365.5mn) investment, announced at International Investment Summit on 14 October, Chan said: “Lilly’s investment, coupled with the UK government’s support for life sciences and healthcare, marks a pivotal moment for the industry.

“By fostering innovation, tackling health challenges like obesity, and driving economic growth, this collaboration highlights the impact of public-private partnerships on national health and economic advancement.”

The initiative will look to advance treatments for obesity, which currently costs the NHS over £11bn ($14.4bn) annually. Eli Lilly is already a major player in the obesity treatment space with its GLP-1R drug Zepbound; there was a shortage of the drug until last week, when the FDA removed it from the shortages list on 19 December.

Lilly’s investment in the UK’s life sciences sector will include a Lilly Gateway Labs facility, which will support startups in the UK’s life science space. The first in Europe and described as an ‘innovation accelerator’, it will include lab space, mentorship, and financial support for startups which are looking to develop transformative medicines.

Chan commented that, “By combining life sciences expertise with healthcare innovation, the effort seeks to deliver lasting health benefits for those affected by obesity.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Her optimism echoed that of science and technology secretary Peter Kyle, who spoke on the announcement of the collaboration in October. He highlighted the collaboration’s role in driving the economy and contributing to “creating the jobs, opportunity, and growth we need to invest further in health and to push up living standards.”

The investment spells good news for the UK government then, which has already shared its plans to promote a healthy life sciences sector. In the budget announced on 30 October, chancellor Rachel Reeves shared plans to provide £520m ($670m) for a new Life Sciences Innovative Manufacturing Fund and committed to maintaining current rates of R&D tax relief.

The budget also included a £25.7bn ($33.6bn) funding boost for the NHS – the largest since 2010 (excluding Covid-19 periods). Key measures for improvements in the NHS included plans for 40,000 extra weekly elective appointments and 18-week treatment targets. They were accompanied by plans to provide £1.5bn ($1.9bn) for surgical hubs enabling 30,000 additional procedures annually, as well as over 1.25 million advanced diagnostic tests.